Capivasertib, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.
Patients for this indication must have tumor tissue confirmed by an FDA-approved test to have one or more PIK3CA/AKT1/PTEN gene alterations, and must have progressed in a metastatic setting after receiving at least one endocrine therapy, or relapsed within 12 months after completing adjuvant endocrine therapy.
